Showing 3981-3990 of 5771 results for "".
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Oyster Point Pharma Receives FDA Approval of Tyrvaya Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-receives-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2480356/Oyster Point Pharma announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. The approval marks the first and only nasal spray approved for the treatment of dry eye disease. Tyrvaya&n
- Kriya Therapeutics Appoints Theresa Heah, MD, as Chief Medical Officer and President of Kriya Ophthalmologyhttps://modernod.com/news/kriya-therapeutics-appoints-theresa-heah-md-as-chief-medical-officer-and-president-of-kriya-ophthalmology/2480354/Kriya Therapeutics announced the appointment of Theresa Heah, MD, MBA, as Chief Medical Officer and President of Kriya’s newly launched ophthalmology division, Kriya Ophthalmology. Dr Heah will be responsible for advancing Kriya’s current pipeline of ophthalmology gene therapies and c
- Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2021-in-communities-worldwide-with-programs-for-improved-access-to-eye-care/2480353/Alcon celebrates World Sight Day 2021 by taking action in communities across the globe to raise awareness of blindness and vision impairment as global public health issues. Celebrated annually in October, World Sig
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- New 4-Year Data Show Genentech’s Enspryng Significantly Reduces Debilitating Relapses in People with NMOSDhttps://modernod.com/news/new-4-year-data-show-genentechs-enspryng-significantly-reduces-debilitating-relapses-in-people-with-neuromyelitis-optica-spectrum-disorder/2480350/Genentech announced new longer-term efficacy and safety data for Enspryng (satralizumab-mwge). The data show Enspryng has a favorable benefit-risk profile and is effective in reducing relapses over 4 years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD, a
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- Stephen D. McLeod, MD, Selected as Next CEO of American Academy of Ophthalmologyhttps://modernod.com/news/stephen-d-mcleod-md-selected-as-next-ceo-of-american-academy-of-ophthalmology/2480346/The American Academy of Ophthalmology board of trustees announced the unanimous selection of Stephen D. McLeod, MD, 57, as the Academy’s next chief executive officer (CEO). Dr. McLeod currently is the Theresa M. and Wayne M. Caygill, M.D. Distinguished Professor and Chair, Department of Oph
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- Glaukos Featured in Numerous Scientific Abstracts at 2021 ESCRShttps://modernod.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-2021-escrs/2480335/Glaukos announced that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting, being held October 8-11, 2021, in Amsterdam, Netherlands. Key Glaucoma Presentations: P